You are viewing: South Korea Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The South Korea Leukapheresis Market was valued at $2.09 Million in 2026 and projected to reach to $3.22 Million by 2031, representing a compound annual growth rate of 9.0%. South Korea's leukapheresis market demonstrates robust growth potential driven by increasing prevalence of hematologic malignancies and expanding cell therapy applications.

South Korea Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Leukapheresis Market Trends and Insights

  • This 9.0% compound annual growth rate reflects South Korea's advancing healthcare infrastructure and increasing adoption of cell therapy technologies.
  • South Korea's commitment to precision medicine and regenerative therapies is driving demand for leukapheresis procedures, which are critical for isolating white blood cells in therapeutic applications. The South Korea leukapheresis market benefits from the country's robust biotechnology sector and government support for innovative medical treatments.
  • South Korea's aging population and rising prevalence of hematologic malignancies are key factors propelling market growth through 2031.
  • Additionally, South Korea's strong regulatory framework and investment in clinical research facilities are accelerating the adoption of advanced leukapheresis technologies among healthcare providers..

Key Market Statistics

  • CAGR (2026-2031) 9.0% CAGR
  • Market Size, 2026 ~USD 2.09 Million
  • Forecast, 2031 ~USD 3.22 Million
  • Country South Korea

South Korea Leukapheresis Market Overview

Market Growth Trajectory :

South Korea's leukapheresis market is expanding at a 9.0% CAGR, growing from $2.09 million in 2026 to $3.22 million by 2031, outpacing the global average of 8.9%.

Advanced Healthcare Infrastructure :

South Korea's state-of-the-art medical facilities and high healthcare spending per capita create an ideal environment for adoption of sophisticated leukapheresis technologies and cell therapy applications.

Precision Medicine Leadership :

The country's strong commitment to precision medicine and regenerative therapies drives demand for leukapheresis procedures, positioning it as a key market for innovative cell-based treatments.

Regulatory Support & Innovation :

South Korea's progressive regulatory framework and government investment in biotechnology foster rapid commercialization of leukapheresis devices and cell therapy protocols.

South Korea Leukapheresis Market Dynamics

  • The country's advanced healthcare system, coupled with strong government support for biotechnology innovation, creates favorable conditions for market expansion.
  • Healthcare providers are increasingly adopting leukapheresis technologies to support CAR-T cell therapy and other cellular immunotherapies. The market is expected to benefit from rising patient awareness, growing clinical trial activities, and enhanced reimbursement policies for cell-based therapies.
  • South Korea's aging population and increasing cancer incidence rates further support market growth.
  • Strategic partnerships between domestic healthcare institutions and international biotech companies will accelerate technology adoption and market penetration through 2031..

Related Ecosystem

Key Takeaways

  • South Korea's leukapheresis market is valued at $2.09 million in 2026 and is expected to reach $3.22 million by 2031.
  • South Korea demonstrates a 9.0% CAGR, driven by advances in cell therapy and regenerative medicine adoption.
  • South Korea's aging demographic and increasing hematologic malignancy prevalence are primary growth catalysts.
  • South Korea's strong biotech ecosystem and regulatory support are accelerating leukapheresis technology deployment.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

South Korea Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

Target Audience

  • Medical Device Manufacturers : Manufacturers need South Korea-specific market data to assess market potential, identify distribution channels, and develop localized product strategies for leukapheresis equipment.
  • Biotechnology & Pharma Companies : Biotech firms require insights into South Korea's cell therapy landscape, clinical adoption rates, and regulatory pathways to support CAR-T and other cellular therapy commercialization efforts.
  • Healthcare Providers & Hospitals : Hospital administrators and clinical directors need market intelligence to justify investments in leukapheresis infrastructure and understand competitive positioning within South Korea's healthcare system.
  • Investment & Private Equity Firms : Investors require detailed South Korea market analysis to evaluate investment opportunities in leukapheresis companies, cell therapy startups, and healthcare technology ventures.
  • Healthcare Consultants & Analysts : Consultants need country-specific market data to provide strategic recommendations to clients operating in or entering South Korea's leukapheresis and regenerative medicine sectors.

Key Companies in the South Korea Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Market-Specific Growth Data : Access precise market sizing and forecasting data exclusive to South Korea, enabling accurate investment decisions and resource allocation in this high-growth Asian market.
  • Competitive Landscape Intelligence : Understand South Korea's unique competitive dynamics, key players, and market positioning to identify partnership opportunities and competitive advantages in the leukapheresis sector.
  • Regulatory & Reimbursement Insights : Gain detailed knowledge of South Korea's regulatory environment, healthcare policies, and reimbursement mechanisms specific to leukapheresis and cell therapy procedures.
  • Clinical Adoption Trends : Identify emerging clinical applications and adoption patterns of leukapheresis in South Korean hospitals and research institutions to guide product development and market entry strategies.
  • Strategic Market Entry Planning : Leverage South Korea-specific insights to develop targeted go-to-market strategies, distribution partnerships, and localization approaches for leukapheresis technologies and services.

Frequently asked questions

What is the current market size of leukapheresis in South Korea?

South Korea's leukapheresis market was valued at $2.09 million in 2026 and is projected to grow to $3.22 million by 2031.

What is the expected growth rate for South Korea's leukapheresis market?

South Korea's leukapheresis market is expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2026 to 2031.

What factors are driving growth in South Korea's leukapheresis market?

South Korea's leukapheresis market growth is driven by advancing healthcare infrastructure, increasing adoption of cell therapy technologies, an aging population, and rising prevalence of hematologic malignancies.

How does South Korea's leukapheresis market compare to global trends?

South Korea's 9.0% CAGR aligns closely with the global market CAGR of 8.9%, indicating that South Korea is experiencing growth rates consistent with worldwide leukapheresis market expansion.

What role does South Korea's biotech sector play in the leukapheresis market?

South Korea's robust biotechnology sector and government support for innovative medical treatments are accelerating the adoption of advanced leukapheresis technologies and driving market expansion.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status